80 completed, 45 active not recruiting, 25 terminated, 24 recruiting. 111 Phase 2, 87 Phase 1, 14 Not applicable, 7 Phase 3, 2 Early Phase 1.
Follow Refractory Multiple Myeloma: new trials by email Literature Review of Refractory Multiple Myeloma trials Research Report on Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-28 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| INfections in Patients Treated With CAR-T Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 290 | 2026-11-01 | 2026-07-20 | |
| FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma FT836 CAR T cells (1 x 10^8 cells per dose), FT836 CAR T cells (3 x 108 cells per dose), FT836 CAR T cells (up to 9 x 108 cells per dose) - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Medical College of Wisconsin | 12 | 2026-10-01 | 2026-08-10 |
| Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | University of California, Davis | 20 | 2026-09-01 | 2026-08-12 |
| TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) Talquetamab, Belantamab mafodotin, Pomalidomide - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Montefiore Medical Center | 50 | 2026-09-01 | 2026-07-22 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Natalie Callander | 62 | 2026-05-21 | 2026-08-31 |
| A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma Biospecimen Collection, Cognitive Intervention, Electronic Health Record Review - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma | Not applicable | Recruiting | Ohio State University Comprehensive Cancer Center | 90 | 2026-04-28 | 2026-05-27 |
| Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2026-04-01 | 2026-05-15 | |
| Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2026-03-24 | 2026-09-16 |
| A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma RO7875913, Placebo, Cevostamab - Healthy Volunteers, Relapsed Multiple Myeloma | Phase 1 | Active not recruiting | Genentech, Inc. | 240 | 2026-03-11 | 2026-09-30 |
| CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma Leukapheresis, Cyclophosphamide, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Suspended | Thomas Martin, MD | 30 | 2026-02-28 | 2026-06-11 |
| DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM DC/MM Fusion Vaccine, GM-CSF - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2026-01-30 | 2026-05-08 |
| Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma Talquetamab, Ciltacabtagene Autoleucel - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Medical College of Wisconsin | 31 | 2025-12-02 | 2026-01-05 |
| Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | Mayo Clinic | 44 | 2025-09-18 | 2026-08-26 |
| Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma Accelerometry, Aerobic Exercise, Biospecimen Collection - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Not applicable | Terminated | Mayo Clinic | 12 | 2025-08-18 | 2026-07-01 |
| Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Talquetamab, Iberdomide, Dexamethasone - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Alfred Chung, MD | 32 | 2025-07-28 | 2026-03-13 |
| Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease Mezigdomide, Carfilzomib, Dexamethasone - Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 28 | 2025-05-01 | 2026-08-18 |
Showing 20 of 199. Sign in to see all of them.
Multiple Myeloma (199) · Leukemia, Lymphocytic, Chronic, B-Cell (36) · Lymphoma, Follicular (34) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (34) · Lymphoma, Large B-Cell, Diffuse (33) · Lymphoma, Non-Hodgkin (33) · Burkitt Lymphoma (32) · Lymphoma (32) · Lymphoma, B-Cell, Marginal Zone (32) · Lymphoma, Mantle-Cell (32) · Lymphoma, Large-Cell, Immunoblastic (29) · Lymphoma, T-Cell, Cutaneous (29) · Waldenstrom Macroglobulinemia (29) · Hodgkin Disease (28) · Mycosis Fungoides (27)
Hemic and Lymphatic Diseases (199) · Blood Protein Disorders (198) · Cardiovascular Diseases (198) · Hemorrhagic Disorders (198) · Hemostatic Disorders (198) · Immune System Diseases (198) · Immunoproliferative Disorders (198) · Lymphoproliferative Disorders (198) · Neoplasms by Histologic Type (198) · Vascular Diseases (198) · Hematologic Diseases (197) · Paraproteinemias (197) · Neoplasms (196) · Neoplasms, Plasma Cell (191) · Lymphatic Diseases (73)
Dexamethasone (50) · Biopsy (34) · Specimen Handling (30) · Calcium Dobesilate (29) · Magnetic Resonance Spectroscopy (26) · Cyclophosphamide (21) · carfilzomib (20) · fludarabine phosphate (20) · Whole-Body Irradiation (19) · Peripheral Blood Stem Cell Transplantation (18) · Bortezomib (17) · Lenalidomide (16) · Mycophenolic Acid (16) · pomalidomide (16) · Cyclosporine (12)
National Cancer Institute (NCI) (61) · Fred Hutchinson Cancer Center (19) · Mayo Clinic (12) · Roswell Park Cancer Institute (6) · Case Comprehensive Cancer Center (5) · University of Washington (5) · City of Hope Medical Center (4) · Medical College of Wisconsin (4) · Thomas Martin, MD (3) · Andrew Yee, MD (2) · Barbara Ann Karmanos Cancer Institute (2) · Dana-Farber Cancer Institute (2) · David Avigan (2) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (2) · Genentech, Inc. (2)
United States (172) · Italy (11) · China (8) · Germany (7) · Australia (3) · Canada (3) · Spain (3) · Taiwan (3) · Belgium (2) · Denmark (2) · France (2) · Switzerland (2) · Turkey (Türkiye) (2) · Austria (1) · Bulgaria (1)
David Maloney (6) · Shaji Kumar (5) · Brenda Sandmaier (4) · David S Hong (3) · Filip Janku (3) · Rahul Banerjee, MD (3) · William Bensinger (3) · Andrew Yee, MD (2) · Anupama Kumar, MD (2) · Binod Dhakal, MD (2) · George Chen (2) · Jacalyn Rosenblatt, MD (2) · Jason J Luke (2) · Jens Hillengass, MD (2)
PMID 32499241, PMID 39501801, PMID 18974373, PMID 19182205, PMID 19900571, PMID 22259028, PMID 22571201, PMID 23887852, PMID 23927993, PMID 23950178, PMID 24241210, PMID 24474568, PMID 25395429, PMID 26331432, PMID 26586415, PMID 26853648, PMID 26943915, PMID 27002117, PMID 27119237, PMID 28148715, PMID 28150872, PMID 28270022, PMID 28683766, PMID 28684537, PMID 28751562, PMID 28803351, PMID 28826616, PMID 29054911, PMID 30562587, PMID 31124580, PMID 31433920, PMID 32145111, PMID 32463741, PMID 32628342, PMID 33048619, PMID 33420905, PMID 33476575, PMID 33492438, PMID 34111952, PMID 35133871, PMID 35138919, PMID 36282798, PMID 36351402, PMID 36656461, PMID 37053535, PMID 37192741, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929
U10CA180820 (33), U24CA196172 (17), P30CA015704 (10), P01CA018029 (4), P01CA078902 (4), N01CM62205 (3), P30CA015083 (3), P30CA016058 (3), U01CA062502 (3), U01CA062505 (3), U01CA076576 (3), U01CA062487 (2), U01CA062491 (2), U01CA069912 (2), U01CA099168 (2)